|
[1] SHIM JJ,OH CH,KIM JW,et al. Liver cirrhosis stages and the incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving antiviral therapy[J]. Scand J Gastroenterol,2017,52(9):1029-1036.
|
|
[2] GOODMAN ZD. Grading and staging systems for inflammation and fibrosis in chronic liver diseases[J]. J Hepatol,2007,47(4):598-607.
|
|
[3] SUN Y,ZHOU J,WU X,et al. Quantitative assessment of liver fibrosis(qFibrosis)reveals precise outcomes in Ishak “stable”patients on anti-HBV therapy[J]. Sci Rep,2018,8(1):2989.
|
|
[4] KIM SU,JUNG KS,LEE S,et al. Histological subclassification of cirrhosis can predict recurrence after curative resection of hepatocellular carcinoma[J]. Liver Int,2014,34(7):1008-1017.
|
|
[5] WU S,KONG Y,PIAO H,et al. On-treatment changes of liver stiffness at week 26 could predict 2-year clinical outcomes in HBV-related compensated cirrhosis[J]. Liver Int,2018,38(6):1045-1054.
|
|
[6] KONG Y,SUN Y,ZHOU J,et al. Early steep decline of liver stiffness predicts histological reversal of fibrosis in chronic hepatitis B patients treated with entecavir[J]. J Viral Hepat,2019,26(5):576-585.
|
|
[7] QI X,AN W,LIU F,et al. Virtual hepatic venous pressure gradient with CT angiography(CHESS 1601):A prospective multicenter study for the noninvasive diagnosis of portal hypertension[J]. Radiology,2019,290(2):370-377.
|
|
[8] VILLANUEVA C,ALBILLOS A,GENESCJ,et al．βblockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension(PREDESCI):A randomised,double-blind,placebo-controlled,multicentre trial[J].Lancet,2019,393(10181):1597-1608.
|
|
[9] GRADY D,BERKOWITZ SA. Why is a good clinical prediction rule so hard to find?[J]. Arch Intern Med,2011,171(19):1701-1702.
|
|
[10] TANGRI N,KENT DM. Toward a modern era in clinical prediction:The TRIPOD statement for reporting prediction models[J]. Am J Kidney Dis,2015,65(4):530-533.
|
|
[11] PAPATHEODORIDIS GV,CHAN HL,HANSEN BE,et al. Risk of hepatocellular carcinoma in chronic hepatitis B:Assessment and modification with current antiviral therapy[J]. J Hepatol,2015,62(4):956-967.
|
|
[12] WONG GL,CHAN HL,WONG CK,et al. Liver stiffnessbased optimization of hepatocellular carcinoma risk score in patients with chronic hepatitis B[J]. J Hepatol,2014,60(2):339-345.
|
|
[13] KIM JH,KIM YD,LEE M,et al. Modified PAGE-B score predicts the risk of hepatocellular carcinoma in Asians with chronic hepatitis B on antiviral therapy[J]. J Hepatol,2018,69(5):1066-1073.
|
DownLoad: